Skip to main content

Table 4 The effects of the triptolide nanoemulsion gels on the chronic dermatitis/eczema mice model (\(\overline{x}\) ± s, n = 12, mm)

From: Development of triptolide-nanoemulsion gels for percutaneous administration: physicochemical, transport, pharmacokinetic and pharmacodynamic characteristics

Score group

First

Second

Third

Fourth

d1

d2

d3

d1

d2

d3

d1

d2

d3

d1

Model

1.23 ± 0.53

1.11 ± 0.66

1.02 ± 0.22

1.77 ± 0.54

2.33 ± 0.79

3.05 ± 0.89

4.55 ± 0.48

4.22 ± 1.15

4.15 ± 0.97

4.63 ± 1.32

Low dosage

1.85 ± 0.86

1.21 ± 0.75

1.01 ± 0.35

1.44 ± 0.65

2.25 ± 0.64

3.12 ± 1.11

3.88 ± 0.54

3.60 ± 0.71

3.15 ± 1.16

4.49 ± 1.23

Middle dosage

0.56 ± 0.23

0.44 ± 0.18

0.46 ± 0.51

0.62 ± 0.52

0.84 ± 0.26

1.21 ± 0.32

1.55 ± 1.02

1.84 ± 0.55

2.03 ± 0.58

2.25 ± 0.95**

High dosage

0.87 ± 0.68

0.99 ± 0.54

0.46 ± 0.29

0.11 ± 0.42

0.96 ± 0.26

0.99 ± 0.63

1.59 ± 0.19

1.85 ± 0.49

2.32 ± 0.62

2.29 ± 1.09**

Tablet

0.77 ± 0.64

0.85 ± 0.27

0.81 ± 0.57

0.91 ± 0.19

1.32 ± 0.31

1.97 ± 0.94

1.85 ± 0.44

1.75 ± 0.83

1.85 ± 0.14

2.24 ± 1.11**

  1. ** P < 0.01 vs. model group